Welcome to our dedicated page for Elicio Therapeutics SEC filings (Ticker: ELTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Elicio Therapeutics’ SEC filings can feel like decoding a clinical protocol. Every 10-K is packed with trial design details, patent diagrams and dilution math that even seasoned analysts find taxing. If you have ever searched “Elicio Therapeutics SEC filings explained simply” or wondered where to locate “Elicio Therapeutics quarterly earnings report 10-Q filing,” this page was built for you.
Stock Titan pairs biotech expertise with AI to break down the language, surface the numbers and highlight what matters. Our engine delivers real-time alerts the moment an “Elicio Therapeutics Form 4 insider transactions real-time” notice hits EDGAR and writes plain-English briefs so you are understanding Elicio Therapeutics SEC documents with AI, not skimming 200 pages.
- 10-K & 10-Q: See R&D spend trends, cash runway and trial milestone timelines in an “Elicio Therapeutics annual report 10-K simplified” or bite-sized “Elicio Therapeutics earnings report filing analysis.”
- Form 4: Track “Elicio Therapeutics insider trading Form 4 transactions” and deeper “Elicio Therapeutics executive stock transactions Form 4” to spot alignment between management and shareholders.
- 8-K: Get concise alerts when an “Elicio Therapeutics 8-K material events explained” filing announces new data, financings or partnerships.
- DEF 14A: Review the “Elicio Therapeutics proxy statement executive compensation” section without wading through compensation tables.
Beyond lists of documents, our AI highlights potential dilution triggers, KRAS vaccine trial updates, and AMP platform IP developments—insights that directly shape valuation. Whether you ask, “How do I read Elicio Therapeutics’ 10-K?” or need instant context before the market opens, you will find every ELTX disclosure here—already clarified.
Elicio Therapeutics (ELTX) filed a resale registration covering up to 103,225 shares of common stock, issuable upon exercise of a warrant issued on June 3, 2025 to GKCC, LLC. The company will not receive proceeds from any sales by the selling stockholder; it may receive cash proceeds only if the warrant is exercised. The warrant is immediately exercisable, expires five years from issuance, and has a $7.75 per share exercise price, subject to a 49.99% beneficial ownership cap.
The selling stockholder may sell shares from time to time through public or private transactions at market or negotiated prices, using methods listed in the plan of distribution, including short sales after the registration statement is declared effective. ELTX trades on Nasdaq; the last reported sale price was $9.19 on November 12, 2025. As context, shares outstanding were 17,413,843 as of October 31, 2025; this is a baseline figure, not the amount being offered.
Elicio Therapeutics (ELTX) reported Q3 2025 results with a net loss of $10.1 million and total operating expenses of $8.0 million, down from $10.3 million a year ago. Year to date, net loss was $31.9 million.
Cash and cash equivalents were $20.6 million as of September 30, 2025. Management disclosed that these resources and expected needs raise substantial doubt about the company’s ability to continue as a going concern. Stockholders’ equity improved to $3.8 million from a $(11.3) million deficit at year-end 2024, reflecting capital actions.
During 2025, Elicio converted a $20.0 million senior secured convertible note (plus $0.3 million interest) into 3,500,573 shares in March, raised $9.2 million net in a January registered direct offering with accompanying warrants, generated $11.4 million net via ATM sales, and issued a $10.0 million senior secured promissory note in June with a warrant. Shares outstanding were 17,489,516 as of November 10, 2025.
Elicio Therapeutics (ELTX) filed an 8-K announcing financial results for the quarter ended September 30, 2025 and providing corporate updates. The company furnished a press release as Exhibit 99.1 with additional details.
The information furnished, including Exhibit 99.1, is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated.
Actyus Private Equity SGIIC, S.A. filed a Schedule 13G/A reporting beneficial ownership of 268,564 shares of Elicio Therapeutics, Inc. common stock, representing
Elicio Therapeutics, Inc. (ELTX) filed a Form 8-K reporting a material event and included three exhibits: a press release dated
The filing supplies named exhibits that investors can review for trial details and corporate messaging; the 8-K itself does not disclose additional numerical trial outcomes in the provided excerpt, so readers should consult the attached press release, presentation, and Exhibit 99.2 for complete data.
Elicio Therapeutics reported that follow-up data from its Phase 1 AMPLIFY-201 study of ELI-002 were published in the peer-reviewed journal Nature Medicine. The company issued a press release announcing the publication, which is attached to this report as Exhibit 99.1 and incorporated by reference. The filing identifies the company as a Delaware corporation with common stock trading under the ticker ELTX on The Nasdaq Capital Market. This disclosure is limited to the publication notice and the inclusion of the press release as an exhibit; no financial results, trial outcomes, or operational actions are presented within the report.
FAQ
What is the current stock price of Elicio Therapeutics (ELTX)?
What is the market cap of Elicio Therapeutics (ELTX)?
